Company news
Gh Research Plc (NASDAQ:GHRS) news
Gh Research Plc news releases on 6ix. Latest, Jun 4, 2026: GH Research Announces Publication of Phase 2a Postpartum Depression Results
Press releases & updates
GH Research Announces Publication of Phase 2a Postpartum Depression Results
June 3, 2026
GH Research Reports First Quarter 2026 Financial Results and Provides Business Update
May 13, 2026
GH Research Announces Pricing of $117.5 Million Underwritten Offering
April 29, 2026
GH Research Welcomes White House Executive Order to Accelerate Medical Treatments for Serious Mental Illness
April 20, 2026
GH Research Announces Publication of Phase 2b Results for Mebufotenin (GH001) in JAMA Psychiatry and Reports New Finding of Severity-Independent Efficacy in TRD
March 24, 2026
GH Research Reports Full Year 2025 Financial Results and Provides Business Update
March 4, 2026
GH Research Announces FDA Lifts Clinical Hold on GH001, Clearing Path for Global Phase 3 Initiation in 2026
January 4, 2026
GH Research to Announce IND Status for GH001
January 1, 2026
GH Research Reports Third Quarter 2025 Financial Results and Provides Business Updates
November 5, 2025
GH Research Announces Novel Therapies Symposium Presentation and Posters at the 2025 ECNP Congress
October 8, 2025
GH Research Reports Second Quarter 2025 Financial Results and Provides Business Updates
August 6, 2025
GH Research Announces Global Pivotal Program Plans and Further Development Updates
July 22, 2025
GH Research Submits Complete IND Hold Response to FDA Ahead of Schedule
June 19, 2025
GH Research Announces Acceptance of Pharmaceutical Pipeline Presentation and Late-Breaking Posters at the American Society of Clinical Psychopharmacology 2025 Annual Meeting
May 14, 2025
GH Research Reports First Quarter 2025 Financial Results and Provides Business Updates
May 7, 2025
GH Research Reports Full Year 2024 Financial Results and Provides Business Updates
February 26, 2025
GH Research Announces Pricing of $150 Million Public Offering
February 4, 2025
GH Research Announces Proposed Public Offering
February 2, 2025
GH Research Announces Primary Endpoint Met in Phase 2b Trial with GH001 in TRD Demonstrating -15.5 Point Placebo-adjusted MADRS Reduction
February 2, 2025
GH Research to Provide Update on Phase 2b Trial with GH001 in TRD
January 30, 2025
GH Research Announces Primary Endpoint Met in Two Phase 2a POC Trials with GH001 and Completion of All FDA Requests to Address IND Hold with No Findings of Respiratory Toxicity in Non-Rodents
January 9, 2025
GH Research Reports Third Quarter 2024 Financial Results and Provides Business Updates
November 13, 2024
GH Research Reports Second Quarter 2024 Financial Results and Provides Business Updates
September 2, 2024
GH Research Announces Appointment of Dr. Velichka “Villy” Valcheva to Chief Executive Officer
September 2, 2024
GH Research Reports First Quarter 2024 Financial Results and Provides Business Updates
May 2, 2024
GH Research Reports Full Year 2023 Financial Results and Provides Business Updates
February 28, 2024
GH Research Announces Grant of European Patent Covering all Mebufotenin (5-MeO-DMT) and Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant Depression
January 17, 2024
GH Research Reports Third Quarter Financial Results and Provides Business Updates
November 8, 2023
GH Research Provides Updates and Guidance on its Clinical Development Program for GH001 in Treatment-Resistant Depression
September 28, 2023
GH Research Reports Second Quarter 2023 Financial Results and Provides Business Updates
August 22, 2023
GH Research Reports First Quarter 2023 Financial Results and Provides Business Highlights
May 10, 2023
GH Research Reports Full Year 2022 Financial Results and Provides Business Updates
March 1, 2023
GH Research Provides Business Updates and Highlights Key Upcoming Milestones
January 8, 2023
GH Research Reports Third Quarter 2022 Financial Results and Provides Business Updates
November 9, 2022
GH Research Reports Second Quarter 2022 Financial Results and Provides Business Updates
August 22, 2022
GH Research Reports First Quarter 2022 Financial Results and Provides Business Updates
May 17, 2022
GH Research Reports Full Year 2021 Financial Results and Provides Business Updates
March 27, 2022
GH Research Reports Third Quarter 2021 Financial Results and Provides Business Updates
December 5, 2021
GH Research Announces Successful Outcome of the Phase 2 part of its Phase 1/2 Clinical Trial of GH001 in Treatment-Resistant Depression
December 5, 2021
GH Research PLC Provides Business Updates and Reports Second Quarter 2021 Financial Results
September 22, 2021